- Home
- HRTX vs SSSS Comparison
HRTX vs SSSS Comparison
Compare HRTX & SSSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$0.94
Company Overview
Basic Information| Metric | HRTX | SSSS |
|---|---|---|
| Founded | 1983 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 265.9M | 233.4M |
| IPO Year | 2007 | N/A |
Fundamental Metrics
Financial Performance| Metric | HRTX | SSSS |
|---|---|---|
| Price | $0.94 | $10.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $4.50 | ★ $11.38 |
| AVG Volume (30 Days) | ★ 1.9M | 195.6K |
| Earning Date | 05-28-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.74% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $154,904,000.00 | N/A |
| Revenue This Year | $15.28 | N/A |
| Revenue Next Year | $20.29 | $17.65 |
| P/E Ratio | ★ N/A | $3.61 |
| Revenue Growth | ★ 7.36 | N/A |
| 52 Week Low | $0.93 | $4.21 |
| 52 Week High | $2.61 | $10.34 |
Technical Indicators
Market Signals| Indicator | HRTX | SSSS |
|---|---|---|
| Relative Strength Index (RSI) | 29.12 | 59.55 |
| Support Level | N/A | $8.58 |
| Resistance Level | $1.36 | $10.34 |
| Average True Range (ATR) | 0.09 | 0.43 |
| MACD | -0.02 | 0.09 |
| Stochastic Oscillator | 2.76 | 87.17 |
Price Performance
Historical Comparison HRTX
SSSS
About HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
About SSSS SuRo Capital Corp.
SuRo Capital Corp is a non-diversified closed-end management investment company. The company's investment objective is to maximize its portfolio's total return, principally by seeking capital gains on its equity and equity-related investments.